GMT – Page 8 – Communicable Diseases Research

Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant

Article

Published on 2021-11-272022-10-31
Journal: Diagnostics [Category] COVID-19,

Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients

Research Article

Published on 2021-09-222022-10-30
Journal: Microbiology Spectrum [Category] COVID-19, MERS, SARS,

[키워드] 95% CI 95% confidence interval acute phase acute respiratory syndrome administration age anti-SARS-CoV-2 antibody antibodies antibody Characteristics China collected conducted convalescent COVID-19 patient Convalescent patients coronavirus coronavirus disease COVID-19 COVID-19 convalescent patient COVID-19 patient Dilution discharge discharged disease severity enrolled Evidence Factor Follow-up follow-up period follow-up time geometric mean titer GMT hospital IgG IgM IgM/IgG immune response inhibitory interquartile range Jiangsu Kinetics male median Month natural infection Neutralizing activity neutralizing antibody Onset participant Patient patients persistence plasma sample produced SARS-CoV-2 serological seropositive serum sample severity significantly higher significantly lower Specific Standard deviation symptom onset tested Vaccine virus dynamics with COVID-19
[DOI] 10.1128/Spectrum.00590-21 PMC 바로가기 [Article Type] Research Article

The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum

SARS-CoV-2 회복기 혈청의 중화 활성 및 RBD 결합에 대한 스파이크 N501Y 돌연변이의 영향

Article

Published on 2021-09-012022-09-11
Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단,

[키워드] 95% CI Amino acid amino acids ANOVA Anti-RBD IgG Anti-S1 antibody Antibody binding assays B.1.1.7 B.1.351 binding binding domain clinician collected convalescent sera convalescent serum COVID-19 COVID-19 patient determine enzyme immunoassay evaluated geometric geometric mean geometric mean titer GMT Hong Kong IgG isolates K417N Lineage mean difference Michael microneutralization N501Y N501Y mutation neutralization Neutralizing activity neutralizing antibody Neutralizing antibody Spike protein receptor binding domain NSP2 one-way ANOVA Patient positive Protein RBD RBD binding Receptor binding Receptor binding domain recovered COVID-19 patient reduced Richard SARS-CoV-2 SARS-CoV-2 isolate SARS-CoV-2 lineage SARS-CoV-2 N501Y variant B.1.1.7 sensitivity sera serum service significantly spike Spike protein Spike receptor binding domain Spread statistically susceptibility symptom onset tested variant variants virus virus variant virus variants viruses VoC VOC. was determined wild-type
[DOI] 10.1016/j.ebiom.2021.103544 PMC 바로가기 [Article Type] Article

Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection

Research Article

Published on 2021-08-272022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] acute COVID-19 administration analyzed antibodies antibody antigenic baseline binding children children with MIS-C clinical response collected coronavirus coronavirus disease correlated correlation COVID-19 determine dose Effect Endemic GMT group healthy children healthy control healthy controls HKU1 Hospitalized IgG antibody Immunity Inflammatory injected injection intramuscular intramuscularly mice MIS-C murine Neutralizing neutralizing antibody Neutralizing antibody response objective original regimen response Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralization SARS-CoV-2 spike SARS-CoV-2 spike protein Serologic response significantly higher spike IgG Spike protein syndrome
[DOI] 10.1371/journal.pone.0256482 PMC 바로가기 [Article Type] Research Article

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

성인에서 COVID-19에 대한 재조합 직렬 반복 이량체 RBD 기반 단백질 서브유닛 백신(ZF2001)의 안전성 및 면역원성: 2건의 무작위 배정, 이중 맹검, 위약 대조, 1상 및 2상 시험

Clinical Trial

Published on 2021-08-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단,

[키워드] 95% CI Abstract Academy adverse event age allergy antibodies Antigen appear assigned Beijing biopharmaceutical center China Chinese Chongqing Contact Control COVID-19 COVID-19 cases COVID-19 vaccine determine development dimeric dose double-blind drug Efficacy eligible enrolled enrolment FIVE Follow-up geometric mean titre GMT group help immunogenic immunogenicity data intention-to-treat intramuscularly Laboratory magnitude Major material mechanism Mild moderate neutralising antibody Occurrence participant Participants per-protocol Phase 1 phase 1 trial phase 2 trial phase 3 trial Placebo placebo group placebo-controlled prevention Primary outcome priority Program protein subunit vaccine randomised Randomly RBD RBD-based protein subunit receive Registered reported Safety SARS-CoV SARS-CoV-2 SARS-COV-2 infection Science second dose Serious Adverse Event Serious Adverse Events seroconversion rate Seven Spike protein Spread Support technology the placebo group the receptor-binding domain the SARS-CoV-2 the vaccine translation Trial trials university hospital vaccination Vaccine vaccine group Vaccines was done ZF2001
[DOI] 10.1016/S1473-3099(21)00127-4 PMC 바로가기 [Article Type] Clinical Trial

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

18 세 이상의 건강한 인구에서 재조합 코비드 -19 백신 (SF9 세포)의 안전성 및 면역 원성 : 2 개의 단일 센터, 무작위, 이중 맹검, 위약 대조, 1 상 및 2 상 시험의 안전성 및 면역 원성

Clinical Trial

Published on 2021-07-152022-08-13
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, SARS, 임상,

[키워드] (phase 1 (phase 2 (phase 2) 95% CI Adverse reaction Adverse reactions antibody assigned candidate vaccine China cough COVID-19 vaccine COVID-19 vaccines dose double-blind Eligible participants ELISA enrolled fatigue Fever GMT GMTs headache healthy High dose high dose vaccine highest immune response immune responses immunogenicity injection live SARS-CoV-2 low dose vaccine Neutralising Antibodies neutralising antibody Older Pain participant peaked Phase 1 phase 1 trial Phase 2 phase 2 trial Placebo placebo-controlled problem randomised Randomly receive recombinant COVID-19 vaccine Safe Safety schedule Sf9 cells single-center sore throat Specific Specific T-cell response T-cell Response Tolerability Trial trials vaccination Vaccine Vaccines
[DOI] 10.1038/s41392-021-00692-3 PMC 바로가기 [Article Type] Clinical Trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

비활성화된 SARS-CoV-2 백신, BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 다기관, 2상 시험 및 이중 맹검, 무작위 1상 시험의 3개월 추적 조사의 중간 결과

Clinical Trial

Published on 2021-07-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단,

[키워드] 1:1 95% CI Abstract addition Administered Antigen assigned baseline Bharat block blood draw cell-mediated immune response clinical trial collected defined dose double-blind Efficacy elevated elicited enrolled evaluate first dose Follow-up geometric mean GMT healthy high neutralising antibody Hindi hospital humoral inactivated India intramuscular dose investigators Local material microneutralisation test MNT multicentre neutralisation test neutralising antibody titre nine outcomes participant phase 1 trial Phase 2 study phase 2 trial Phase 3 positive Primary outcome PRNT proportion randomisation randomised Randomly reactogenicity receive Registered remained reported response Safety SARS-CoV-2 SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened second dose second vaccination secondary outcome selected Serious Adverse Event seroconversion rate serology test significant difference significantly higher Sponsor T-cell Response Th1 phenotype the vaccine titre Toll-like receptor translation treatment group Trial Vaccine was done were assessed were excluded wild-type
[DOI] 10.1016/S1473-3099(21)00070-0 PMC 바로가기 [Article Type] Clinical Trial

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Ad26.COV2.S 코비드-19 백신의 1-2a상 시험 중간 결과

Clinical Trial

Published on 2021-05-132022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus administration adverse event age All participants Antibody Response assigned authority candidate vaccine CD4+ T-cell CD8+ T-cell Cohort cohorts collected coronavirus coronavirus disease Coronavirus disease 2019 COV1001 COV2.S Department development dose Factor fatigue Fever full-length geometric mean geometric mean titer GMT headache healthy High dose Human increase in Infection Injection-site pain Interim Johnson & Johnson less low dose milliliter multicenter myalgia Neutralizing-antibody Neutralizing-antibody titers Older pandemic participant phase Placebo placebo-controlled primary end point profile provided Randomly reached reactogenicity receive regimen remained reported research and development respiratory response responses Result robust SARS-CoV-2 SARS-CoV-2 spike protein second dose serotype severe acute respiratory syndrome Coronavirus Spike protein Support systemic systemic adverse events T cells T-cell responses titer titers Trial two-dose regimen type 1 helper Vaccine vaccine candidate vaccine dose Viral viral particle wild-type virus
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial

Are There Any Parameters Missing in the Mathematical Models Applied in the Process of Spreading COVID-19?

Article

Published on 2021-02-192022-10-28
Journal: Biology [Category] COVID-19,

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Research

Published on 2021-02-082022-10-05
Journal: Nature Medicine [Category] SARS, 변종,

[키워드] acute respiratory syndrome African BNT162b2 coronavirus doses E484K Effect elicited geometric mean titer GMT GMTs human sera mutant virus Mutation N501Y neutralization parental SARS-CoV-2 SARS-CoV-2 spike sera South spike mutation United Kingdom variant virus
[DOI] 10.1038/s41591-021-01270-4 [Article Type] Research